10/09/2026
🇲🇽 UN LLAMADO DE ATENCIÓN SOBRE LOS MEDICAMENTOS GLP-1
32 millones de estadounidenses usan GLP-1 de la marca Eli Lilly & Co., la misma empresa que fabrica las vacunas contra el COVID. Sus precios en los Estados Unidos son exorbitantes, aun cuando estas farmacéuticas cuentan con billones de dólares en grants de dinero de los estadounidenses, provenientes de impuestos para la investigación de medicamentos para la obesidad.
Estas son las mismas farmacéuticas, como Pfizer, Lilly, Moderna y Johnson & Johnson, que donan cantidades fuertes a senadores, hospitales, al sistema de salud de Estados Unidos, a la FDA y, quién sabe, si también a COFEPRIS. Y son las únicas farmacéuticas que aceptan los servicios sociales de Estados Unidos, como el Bridge Program, para proveer este medicamento GLP-1 a Medicare Parte D como beneficio.
No solo esto: muchos de los senadores y servidores públicos cuentan con acciones de estas empresas. Por esto mismo, les aceptan todo y tienen el monopolio total de médicos, universidades, hospitales, clínicas y programas de gobierno, y se atreven a seguir usando compuestos tóxicos en todos sus productos para la humanidad.
En México, con la necesidad tan grande que existe debido a la diabetes, la obesidad y las enfermedades de nuestra civilización, aun sabiendo que los productos compuestos son mucho más económicos y seguros, COFEPRIS nomás aceptó que estas empresas asesinas y abusivas entren a México con precios exorbitantes.
Morena, es tiempo de no mirar hacia otro lado. México necesita este fármaco GLP-1.
Este es un llamado de atención hacia nuestro gobierno.
Doctoral Research Article Systemic Negligence in Pharmaceutical Preservation: Phenol Exposure in Lilly’s GLP‑1 Injectables Compared to RxPros Compounded Alternatives Abstract
This article investigates the repeated use of phenol, a toxic preservative, in Lilly’s GLP‑1 injectables (tirzepatide/Zepbound and semaglutide/Wegovy). Drawing on ATSDR toxicological profiles, WHO drinking water guidelines, and FDA package inserts, it demonstrates that repeated injections expose patients to cumulative phenol doses far above environmental safety limits. In contrast, RxPros compounded GLP‑1 formulations avoid phenol entirely, relying on vitamins B6/B12 and sterile stabilizers. Legal filings against Lilly alleging insufficient disclosure reinforce the argument of systemic negligence.
Introduction
Pharmaceutical excipients are intended to ensure sterility and stability. However, many are inherently toxic. Phenol (C₆H₅OH) is corrosive and systemically harmful, yet remains in use as a preservative in injectable medicines. Regulators (FDA, WHO) approve its use at micro‑dose levels, but cumulative exposure from repeated injections has not been adequately studied.
Toxicology Evidence
ATSDR Toxicological Profile (2008): “Phenol is corrosive to the eyes, skin, and respiratory tract. Systemic absorption can result in damage to the liver, kidneys, and nervous system.”
WHO Drinking Water Guidelines: “The guideline value for phenol in drinking water is 0.001 mg/L, based on its potential to cause adverse health effects.”
OSHA Workplace Standards: “The permissible exposure limit for phenol is 5 ppm (19 mg/m³) as an 8‑hour time‑weighted average.”
Clinical review (Pain Practice, 2026): Phenol used in neurolysis is effective but associated with neurological risks and systemic toxicity, underscoring its hazardous profile. Case Study: Lilly GLP‑1 Injectables
Active drugs: Tirzepatide (Zepbound), Semaglutide (Wegovy). Excipients: Phenol, benzyl alcohol, glycerin, sodium chloride, phosphate buffer, sterile water. Exposure: ~2–3 mg phenol per injection; four monthly injections ≈ 10 mg.
Risk: Below acute toxicity thresholds, but cumulative exposure exceeds WHO environmental safety limits.
Negligence: Reliance on phenol despite safer alternatives demonstrates disregard for long‑term toxicology.
Case Study: RxPros GLP‑1 Compounded
Active drugs: Tirzepatide or Semaglutide.
Excipients: Vitamins B6/B12, sterile stabilizers.
Absent: Phenol or benzyl alcohol.
Risk profile: Lower excipient toxicity, though compounded drugs depend on pharmacy quality.
Strength: Demonstrates GLP‑1 therapies can be formulated without toxic preservatives.
Legal & Regulatory Controversies
o Novo Nordisk v. Lilly (U.S. District Court, New Jersey, 2026): Lilly’s advertising for Zepbound and Mounjaro is false and misleading because it relies on outdated trial data and omits newer high‑dose Wegovy results, thereby creating a false impression of superior efficacy.”
o Lilly v. Mochi Health (2025): Lilly’s filings confirm that its FDA‑approved tirzepatide formulations contain phenol, while compounded versions may include vitamins instead.
Conclusion Phenol is universally recognized as toxic, yet Lilly continues to use it in GLP‑1 injectables. Repeated monthly injections expose patients to cumulative doses far above WHO environmental safety limits. RxPros compounded alternatives demonstrate that safer excipient profiles are possible. Combined with lawsuits alleging insufficient disclosure, this evidence supports the claim of systemic negligence in Lilly’s reliance on toxic preservatives.
